Research programme: ROR gammaT antagonists - Immunic

Drug Profile

Research programme: ROR gammaT antagonists - Immunic

Alternative Names: IMU-366

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4SC
  • Developer Immunic
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Immunological disorders; Inflammatory bowel diseases; Psoriasis

Most Recent Events

  • 28 Sep 2016 Immunic Therapeutics acquires IMU-366 programme from 4SC
  • 28 Sep 2016 Early research in Autoimmune disorders in Germany before September 2016 (PO)
  • 28 Sep 2016 Early research in Immunological disorders in Germany before September 2016 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top